Loss holds flat year-over-year. Cullinan Therapeutics reported a loss of $0.77 per share for Q4 2025. The biotechnology company posted a net loss of $50.7 million and an operating loss of $55.3 million for the quarter. The company generated no revenue during the period, consistent with its pre-commercial stage as a clinical-stage biopharmaceutical company.
Revenue remains absent. Cullinan Therapeutics recorded zero revenue in Q4 2025, unchanged from the year-ago quarter when revenue was also zero. The company has not generated product revenue in any of the past five quarters, reflecting its focus on advancing clinical-stage oncology and autoimmune programs through development rather than commercialization. Trading volume reached 864,736 shares on the report date, with the stock closing at $15.74.
Sequential burn rate unchanged. The $0.73 per share loss in Q4 2025 matched the prior quarter’s $0.73 loss, suggesting stable operating expenses quarter-over-quarter. The company’s loss per share has ranged from $0.77 to $1.07 over the past five quarters, with Q2 2025 representing the peak burn rate. With 59.1 million shares outstanding and a market capitalization of $904 million, investors are pricing in significant pipeline value despite the ongoing cash consumption.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.